Navigation Links
Palomar Medical to Debut New Devices and a More Powerful Platform at the American Academy of Dermatology Annual Meeting
Date:3/6/2009

that objective and will revolutionize the laser-assisted liposuction industry."

In addition to the introduction of the XD Optic, the GROOVE Optic, LuxPowR pulsed light handpiece and a more powerful Aspire SlimLipo Body Sculpting Laser, the following presentations at AAD will be held in Palomar's trade show booth:

Saturday, March 7

  • 12:00pm - Combining Ablative and Non-Ablative Fractional Handpieces for Maximum Results with Minimum Downtime.
  • 2:00pm - New Advancements in Fractional Treatment of Scars.
  • 3:00pm - True-Laser Lipolysis: The SLIM Procedure(SM) (Selective Laser Induced Melting) Clinical Experience.
  • 4:00pm - Combining Ablative and Non-Ablative Fractional Handpieces for Maximum Results with Minimum Downtime.

Sunday, March 8

  • 10:00am - Success with Lux2940(TM) Fractional Ablation.
  • 11:00am - Cross Selling Aesthetic Treatments with the Beau Visage(TM) System.
  • 1:00pm - True-Laser Lipolysis: The SLIM Procedure(SM) (Selective Laser Induced Melting) Clinical Experience.
  • 2:00pm -Advanced Treatment Strategies in Hair Reduction.
  • 3:00pm - New Advancements in Fractional Treatment of Scars.

Monday, March 9

  • 10:00am - Cross Selling Aesthetic Treatments with the Beau Visage(TM) System.
  • 12:00pm - New Advancements in Fractional Treatment of Scars.
  • 2:00pm - True-Laser Lipolysis: The SLIM Procedure(SM) (Selective Laser Induced Melting) Clinical Experience.
  • 3:00pm - Success with Lux2940(TM) Fractional Ablation.

Management will be available at the AAD for investor demonstrations
'/>"/>

SOURCE Palomar Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008
2. Palomar Medical Technologies to Host Fourth Quarter and Year End 2008 Financial Results Conference Call and Webcast on February 5, 2009
3. Reliant Technologies, and Palomar Medical Technologies, Announce Launch of a Fractional Technology Licensing Program
4. Palomar Medical Technologies and Reliant Technologies Announce Launch of a Fractional Technology Licensing Program
5. Palomar Medical Reports Financial Results for Third Quarter 2008
6. Palomar Medical Technologies to Host Second Quarter 2008 Financial Results Conference Call and Webcast on July 31, 2008
7. Palomar to Unveil New Laser-Assisted Liposuction Platform at the American Society for Laser Medicine & Surgery
8. Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology
9. Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting
10. Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms
11. Palomar Medical Technologies Third Quarter 2007 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... A pilot study by Massachusetts General Hospital (MGH) investigators ... unusual treatment for a serious medical problem use ... diarrhea caused by the Clostridium difficile ( ... published online in the journal Clinical Infectious Diseases ... fecal material from donors unrelated to patients was as ...
(Date:4/23/2014)... researchers say clinical trials for a new experimental ... very promising. Patients treated with CPX-351, a combination ... showing better responses than patients treated with the ... myeloid leukemia is an aggressive blood cancer with ... older patients," explained Jeffrey Lancet, M.D., senior member ...
(Date:4/23/2014)... A Michigan State University researcher is looking to give ... workout, and her latest research shows that a cyber ... the Games for Health Journal , is the ... still a better motivator during exercise, a software-generated partner ... that something that isn,t real can still motivate people ...
(Date:4/23/2014)... University researchers have developed a way to detect and ... tiny gold particles with tails of synthetic DNA., A ... biological engineering, used gold nanoparticles to target and bind ... RNA splice variants, which can indicate the presence and ... splice variants in a cell can be determined by ...
(Date:4/23/2014)... the gastro-intestinal tract has long been considered to be ... Sahlgrenska Academy have used refined microscopic techniques that indicate ... of the gastro-intestinal tract is only as large as ... The digestive tract, which passes from the mouth through ... length of about 5 meters in a normal adult, ...
Breaking Medicine News(10 mins):Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Cyber buddy is better than 'no buddy' 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... Record Profitability and 12th Consecutive Year of Record ... ... $164 ... ST. LOUIS, Feb. 15 KV Pharmaceutical Company,(NYSE: KVa/KVb), a fully integrated ...
... One day doctors may recommend using high efficiency ... smoking cessation, and exercise to improve cardiovascular health, ... study, they found that using HEPA filters for ... of cardiovascular health in healthy, non-smoking elderly individuals. ...
... single prostate specific antigen (PSA) test at age 50 or ... 25 years later, (regardless of clinical significance) have now found ... prostate cancer. , The findings, published in the online ... men would benefit from intensive screening. , More men die ...
... Penn Bancshares Inc. (NASD:,NPBC) will replace Bradley Pharmaceuticals Inc. ... the close of trading on Thursday, February 21, 2008. ... on or about that date,pending final approvals., Standard ... relevant,updates on its website: http://www.standardandpoors.com ., National ...
... killer, but the recent findings of four Texas A&M University ... the dreaded disease. , Diabetics not only have high ... levels because they have trouble metabolizing glucose and fatty acids. ... acid aspects of diabetes separately because there was nothing linking ...
... Following the,company,s announcement of record unaudited revenues ... nutritional product manufacturer subsidiary InterACTIVE,Nutrition International, Inc., ... Board: NNTN) http://www.naturalnutritioninc.com ,announced today the ... common stock.,Each shareholder will receive one additional ...
Cached Medicine News:Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 2Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 3Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 4Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 5Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 6Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 7Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 8Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 9Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 10Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 11Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 12Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 13Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 14Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 15Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 16Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 17Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 18Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 19Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 20Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 21Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 22Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 23Health News:Using HEPA filters may improve cardiovascular health 2Health News:Early warning: PSA testing can predict advanced prostate cancer 2Health News:Standard & Poor's Announces Change to U.S. Index 2Health News:Research findings may lead to new ways to study and fight diabetes 2Health News:Research findings may lead to new ways to study and fight diabetes 3Health News:Natural Nutrition Announces Effectiveness of Forward Split of Common Stock Following 2007 Record Revenue Year 2
(Date:1/14/2014)... a manufacturer of ergonomically designed laboratory equipment for research, ... Japan to sell and service the Hitachi brand ... utilize its network of sales professionals throughout the United ... assistance in application use, product benefits and features, options and accessories, ...
(Date:1/14/2014)... VALHALLA, N.Y. , Jan. 14, 2014   Oligomerix, Inc. ... disease modifying therapeutics for Alzheimer,s disease (AD) and related ... headquarters to Valhalla, NY as ... additional laboratory space at New York Medical College. ...
(Date:1/14/2014)... Evidera , a leading provider of evidence-based solutions for ... Evaluation and Research (CDER), U.S. Food and Drug Administration, ... a patient-reported outcome (PRO) measure in drug development: ... for Measurement of Symptoms of Acute Bacterial Exacerbation of ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... PARIS--(BUSINESS WIRE)--Jun 11, 2007 - Regulatory News-Ipsen,(Paris:IPN) announced ... III study for its investigational 4-month formulation,of triptorelin ... triptorelin for a duration of 4 months in ... the second,administration as planned in the protocol. No ...
... 11, 2007 /PRNewswire/ -- NovaCardia, Inc.,today presented preliminary ... an adenosine A1 receptor antagonist in development for ... (CHF),that indicate a strong trend toward efficacy for ... a higher rate of,improvement in dyspnea, or shortness ...
Cached Medicine Technology:Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration 2Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 2Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 3Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007 4
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek® ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
Medicine Products: